Home > Publications database > Secretogranin II influences the assembly and function of MHC class I in melanoma. > print

001     274237
005     20240229154930.0
024 7 _ |a pmid:36906639
|2 pmid
024 7 _ |a pmc:PMC10007832
|2 pmc
024 7 _ |a DOI: 10.1186/s40164-023-00387-1
|2 doi
024 7 _ |a DOI: 10.1186/s40164-023-00387-1
|2 doi
037 _ _ |a DKFZ-2023-00523
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Steinfass, Tamara
|0 P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488
|b 0
|e First author
|u dkfz
245 _ _ |a Secretogranin II influences the assembly and function of MHC class I in melanoma.
260 _ _ |a London
|c 2023
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1679472052_6241
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:A370#LA:A370#
520 _ _ |a Melanoma is the deadliest form of skin cancer showing rising incidence over the past years. New insights into the mechanisms of melanoma progression contributed to the development of novel treatment options, such as immunotherapies. However, acquiring resistance to treatment poses a big problem to therapy success. Therefore, understanding the mechanisms underlying resistance could improve therapy efficacy. Correlating expression levels in tissue samples of primary melanoma and metastases revealed that secretogranin 2 (SCG2) is highly expressed in advanced melanoma patients with poor overall survival (OS) rates. By conducting transcriptional analysis between SCG2-overexpressing (OE) and control melanoma cells, we detected a downregulation of components of the antigen presenting machinery (APM), which is important for the assembly of the MHC class I complex. Flow cytometry analysis revealed a downregulation of surface MHC class I expression on melanoma cells that showed resistance towards the cytotoxic activity of melanoma-specific T cells. IFNγ treatment partially reversed these effects. Based on our findings, we suggest that SCG2 might stimulate mechanisms of immune evasion and therefore be associated with resistance to checkpoint blockade and adoptive immunotherapy.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HLA
|2 Other
650 _ 7 |a MHC class I
|2 Other
650 _ 7 |a Melanoma
|2 Other
650 _ 7 |a Prognosis
|2 Other
650 _ 7 |a SCG2
|2 Other
700 1 _ |a Poelchen, Juliane
|0 P:(DE-He78)88a268b9173c651561385cddfdf819fa
|b 1
|u dkfz
700 1 _ |a Sun, Qian
|0 P:(DE-He78)f1f0076fc72606659a5df2605acce91b
|b 2
|u dkfz
700 1 _ |a Mastrogiulio, Giovanni
|0 P:(DE-He78)eb931fe38d70f73c17ed3a90ac3664bb
|b 3
|u dkfz
700 1 _ |a Novak, Daniel
|0 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758
|b 4
|u dkfz
700 1 _ |a Vierthaler, Marlene
|0 P:(DE-He78)61de47f47323d5d0b1700e8213e5179f
|b 5
700 1 _ |a Pardo, Sandra
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Federico, Aniello
|0 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9
|b 7
|u dkfz
700 1 _ |a Hüser, Laura
|0 P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211
|b 8
|u dkfz
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 9
|u dkfz
700 1 _ |a Carretero, Rafael
|0 P:(DE-He78)86723b26e79aa190a6c7294651a80986
|b 10
|u dkfz
700 1 _ |a Offringa, Rienk
|0 P:(DE-He78)81ae96953d6149e4307057d71a190019
|b 11
|u dkfz
700 1 _ |a Altevogt, Peter
|0 P:(DE-He78)e6057131c71c90a6fcf61035f12b46c3
|b 12
|u dkfz
700 1 _ |a Umansky, Viktor
|0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
|b 13
|u dkfz
700 1 _ |a Utikal, Jochen
|0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
|b 14
|e Last author
|u dkfz
773 _ _ |a DOI: 10.1186/s40164-023-00387-1
|g Vol. 12, no. 1
|0 PERI:(DE-600)2669066-4
|n 1
|p 29
|t Experimental hematology & oncology
|v 12
|y 2023
|x 2162-3619
909 C O |p VDB
|o oai:inrepo02.dkfz.de:274237
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)88a268b9173c651561385cddfdf819fa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)f1f0076fc72606659a5df2605acce91b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)eb931fe38d70f73c17ed3a90ac3664bb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)86723b26e79aa190a6c7294651a80986
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)81ae96953d6149e4307057d71a190019
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)e6057131c71c90a6fcf61035f12b46c3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP HEMATOL ONCOL : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-22
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EXP HEMATOL ONCOL : 2022
|d 2023-08-22
920 2 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
920 1 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
920 1 _ |0 I:(DE-He78)D220-20160331
|k D220
|l DKFZ -Bayer Healthcare Joint
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 3
920 1 _ |0 I:(DE-He78)D200-20160331
|k D200
|l Molekulare Grundlagen Gastrointestinaler Tumoren
|x 4
920 0 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A370-20160331
980 _ _ |a I:(DE-He78)D220-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)D200-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21